Currently held
- Agent 8 — Dip Buyer (Peer-Aware)long1 sh @ $1,155.29 · stop $1,062.87-$14.24 unrealized
- Agent 7 — Day Traderlong2 sh @ $1,138.50 · stop $1,121.42+$5.09 unrealized
LLY
Lilly(Eli) & CompanyHealth Careinsider_universeLast close $1,141.28Sep 13, 2026
Day +2.29%
Everything we've seen
- ·Sep 14, 2:47 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:47 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 2:47 PMstreamnews
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.
- ·Sep 14, 2:47 PMstreamnews
Top 50 High-Quality Dividend Growth Stocks For September 2026
- ·Sep 14, 2:47 PMstreamnews
OPKO Health (OPK) Cashes In A Future Royalty Stream Early
On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]
- ·Sep 14, 2:30 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:30 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 2:30 PMstreamnews
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.
- ·Sep 14, 2:30 PMstreamnews
Top 50 High-Quality Dividend Growth Stocks For September 2026
- ?Sep 14, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $1064.05 cash available; close=$1137.24.
- ·Sep 14, 2:16 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:16 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 2:16 PMstreamnews
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
- ·Sep 14, 2:16 PMstreamnews
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
- ·Sep 14, 2:00 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 2:00 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 1:46 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:46 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 1:30 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:30 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ?Sep 14, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $1064.05 cash available; close=$1137.24.
- ·Sep 14, 1:15 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:15 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 1:00 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 1:00 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 12:45 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 12:45 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 12:30 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 12:30 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ?Sep 14, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $1064.05 cash available; close=$1137.24.
- ·Sep 14, 12:17 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 12:17 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ❖Sep 14, 12:08 PMnewsvia finnhub
AZN's Etcamah Fails Late-Stage Study for First-line Breast Cancer
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
- ·Sep 14, 12:00 PMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 12:00 PMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 11:46 AMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 11:46 AMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ·Sep 14, 11:30 AMstreamnews
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ·Sep 14, 11:30 AMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ?Sep 14, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] Wanted to buy but only $1064.05 cash available; close=$1137.24.
- ·Sep 14, 11:15 AMstreamnews
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ✓Sep 14, 11:05 AMdecisionacted
Agent 7 — Day Trader — decide: buy
LLY is up 2.04% today with 280 minutes remaining — substantial time for continuation. The news backdrop is modestly supportive: Novo Nordisk's rebranding ('Novo ditches Nordisk') and its worst week since February signals competitive pressure on LLY's primary obesity/GLP-1 rival, which is a relative tailwind for LLY. A big bank maintaining a 45% upside price target headline also provides fundamental support. The Novartis drug race headline adds some competitive noise but is not a direct negative catalyst. Macro context (T10Y2Y at 1.9σ below trend, slight flattening) is more relevant to banks/defensives and is largely neutral for large-cap pharma. There is no clear reversal signal or fade pattern described. The 2% move represents real conviction flow. With ample time remaining and a supportive competitive/news backdrop, continuation is the base case, though conviction is moderate rather than high given the competitive headlines and absence of a pure positive catalyst directly tied to LLY fundamentals today.
- ❖Sep 14, 10:37 AMnewsvia finnhub
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
- ?Sep 14, 10:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1064.05 cash available; close=$1137.24.
- !Sep 14, 10:21 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ❖Sep 14, 8:49 AMnewsvia finnhub
Novo Nordisk rebrands as Novo to compete in obesity market
The Danish drugmaker unveiled a new name, slogan, and set of cultural principles as it trails Eli Lilly in the obesity drug market
- ❖Sep 14, 7:01 AMnewsvia finnhub
Eli Lilly Fell Like a Rock Over the Last Month: This Big Bank Expects 45% Returns Over The Next Twelve
Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock this dominant.
- ?Sep 14, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ❖Sep 14, 5:04 AMnewsvia finnhub
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
- ❖Sep 14, 4:51 AMnewsvia finnhub
NVO Stock Logs Worst Week Since February As Novo Nordisk Rebrands To ‘Novo’ Amid Another Gloomy Year
NVO has fallen about 12% in 2026 after losing more than half its value in 2025, its worst year since 1984.
- ❖Sep 14, 4:41 AMnewsvia finnhub
Novo ditches Nordisk from name as drugmaker attempts revival
Novo Nordisk is shortening its name as part of an effort to boost its appeal to consumers in the obesity drug market, where the Danish drugmaker...
- ❖Sep 14, 3:59 AMnewsvia finnhub
Big Pharma Is Pouring Billions Into China’s Biotechs
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
- ❖Sep 14, 2:57 AMnewsvia finnhub
Novo Nordisk Just Dropped ‘Nordisk’ From Its Name as Obesity Drug Battle With Eli Lilly Heats Up — Here’s Why
Novo Nordisk rebrands as 'Novo' as it seeks to regain obesity drug market share and unveils a new corporate culture.
- ❖Sep 14, 2:55 AMnewsvia finnhub
Wall Street Breakfast Podcast: Oil's New Chokepoint
Another reason oil is sitting above $100. Novo Nordisk is dropping half its name. Trump is making the AI case for speed over caution.
- ❖Sep 13, 11:07 PMnewsvia finnhub
OPKO Health (OPK) Cashes In A Future Royalty Stream Early
On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]
- ❖Sep 13, 7:54 PMnewsvia finnhub
Top 50 High-Quality Dividend Growth Stocks For September 2026
- ❖Sep 13, 5:35 PMnewsvia finnhub
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.
- ❖Sep 12, 7:35 AMnewsvia finnhub
Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]
- ❖Sep 12, 4:49 AMnewsvia finnhub
Benzinga Bulls and Bears: GameStop, Marvell, Robinhood
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
- ?Sep 11, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip_no_cash
Wanted to buy but only $9195.51 cash available; close=$1115.70.
- !Sep 11, 6:04 PMsignal
Agent 4 — Dip Buyer (Frozen) — insufficient_capital
Wanted to buy but only $10524.93 cash available; close=$1149.36.
- ❖Sep 11, 5:10 PMnewsvia finnhub
Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Morgan Stanley sees Eli Lilly taking share before semaglutide's patents even become the bigger issue.
- ?Sep 11, 4:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ?Sep 11, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ❖Sep 11, 3:11 PMnewsvia finnhub
Is AbbVie Stock Actually Overpriced?
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
- ?Sep 11, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ?Sep 11, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ❖Sep 11, 1:20 PMnewsvia finnhub
Could This New Opportunity Be Worth Billions for Novo Nordisk?
The worst may be in the rearview mirror for the drugmaker.
- ?Sep 11, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] Wanted to buy but only $315.03 cash available; close=$1122.70.
- ❖Sep 11, 12:05 PMnewsvia finnhub
Amgen Drops 10% on a Trial It Didn't Even Run
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
- ❖Sep 11, 11:34 AMnewsvia finnhub
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
Morgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook
- ❖Sep 11, 11:26 AMnewsvia finnhub
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
- ❖Sep 11, 9:54 AMnewsvia finnhub
IHE: Innovation Supports The Outlook, Valuation Limits Conviction
IHE trades at a P/E of 16.11x and is rated HOLD due to regulatory, patent, and concentration risks. Click for more details on the IHE fund.
- ❖Sep 11, 9:35 AMnewsvia finnhub
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
- ❖Sep 11, 9:10 AMnewsvia finnhub
Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy
Read this week's top deal updates, including Bending Spoons' Miro deal, Chime's Stride Bank purchase, and the LIV Golf bankruptcy.
- ❖Sep 11, 9:02 AMnewsvia finnhub
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.
- ❖Sep 11, 7:58 AMnewsvia finnhub
Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report
Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.
- ❖Sep 11, 7:40 AMnewsvia finnhub
Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup
Eli Lilly (LLY) combines strong growth, high profitability, and a consolidating chart, offering a potential breakout setup for growth investors.
- ❖Sep 11, 1:00 AMnewsvia finnhub
Growth Without AI: 8 Stock Picks
With products ranging from cardboard boxes to new drugs, these companies are all on track to double their earnings.
- ❖Sep 10, 11:45 PMnewsvia finnhub
Second Quarter Earnings: A Rising AI Tide Lifts Many Sectors
- ❖Sep 10, 11:24 PMnewsvia finnhub
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
- ?Sep 10, 4:26 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $315.03 cash available; close=$1122.70.
- !Sep 10, 4:26 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $120.83 cash available; close=$1124.25.
- ❖Sep 10, 3:10 PMnewsvia finnhub
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.
- ❖Sep 10, 1:57 PMnewsvia finnhub
JNJ Stock: Is the Rally Running Out of Steam?
A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.
- ❖Sep 10, 1:30 PMnewsvia finnhub
Got $10,000? Eli Lilly vs. Nvidia: The Better Buy For 2026
Eli Lilly and Nvidia both just posted stunning quarters riding two of the biggest secular waves in markets today, but a $10,000 bet can only tilt one way. Which secular story holds the sharper edge heading into 2026?
- ❖Sep 10, 12:35 PMnewsvia finnhub
Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy?
Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.
- ❖Sep 10, 11:54 AMnewsvia finnhub
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
- ❖Sep 10, 11:15 AMnewsvia finnhub
Novo Nordisk: Valuation Reflects High Risk, But Solid Margin Of Safety
Novo Nordisk stays a Strong Buy after strong Q2 results and raised guidance. Click for more about the NVO stock.
- ❖Sep 10, 11:05 AMnewsvia finnhub
Why Has AbbVie Gone Quiet About Humira?
AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.
- ❖Sep 10, 10:31 AMnewsvia finnhub
Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
The obesity therapeutics market is becoming increasingly concentrated around an Eli Lilly–Novo Nordisk duopoly, with tirzepatide (ZEPBOUND) and semaglutide (WEGOVY) continuing to dominate the US branded treatment landscape. However, the competitive environment is evolving rapidly with the introduction of oral GLP-1 therapies. Novo Nordisk's oral WEGOVY surpassed 5 million cumulative US prescriptions within 30 weeks, while Eli Lilly's FOUNDAYO gained notable momentum among patients initiating ora
- ❖Sep 10, 6:30 AMnewsvia finnhub
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
This company aims to serve a market heading toward $100 billion.
- ❖Sep 10, 5:57 AMnewsvia finnhub
HSBC Maintains Reduce on Eli Lilly, Raises Price Target to $940
HSBC analyst Rajesh Kumar maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.
- ❖Sep 10, 4:06 AMnewsvia finnhub
The Zacks Analyst Blog Highlights Eli Lilly, Palo Alto, Texas Instruments and Stratus Properties
Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand and strategic moves, while Stratus advances asset sales.
- ❖Sep 10, 12:20 AMnewsvia finnhub
Baron Opportunity Fund Q2 2026 Adds And Trims
Baron Opportunity Fund released its Q2 2026 portfolio updates and key investments. Read the full analysis for more details.
- ❖Sep 9, 4:43 PMnewsvia finnhub
Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments
Eli Lilly, Palo Alto Networks and Texas Instruments benefit from strong demand, strategic moves and growth prospects despite key risks.
- ❖Sep 9, 4:41 PMnewsvia finnhub
What Eli Lilly Was Telling You While It Rationed Its Own Launches
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
- ?Sep 9, 4:25 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $120.83 cash available; close=$1124.25.
- !Sep 9, 4:25 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $16.33 cash available; close=$1123.78.
- ❖Sep 9, 3:12 PMnewsvia finnhub
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]
- ❖Sep 9, 9:57 AMnewsvia finnhub
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary
Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura’s leadership team, and other investors. The stated goal is to advance the company’s work in meni
- ❖Sep 9, 9:07 AMnewsvia finnhub
Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up
Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.
- ❖Sep 9, 8:11 AMnewsvia finnhub
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
- ❖Sep 9, 7:54 AMnewsvia finnhub
Kura spins diabetes work into a Lilly-backed biotech startup
Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
- ❖Sep 9, 7:00 AMnewsvia finnhub
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres
- ?Sep 8, 4:22 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $16.33 cash available; close=$1123.78.
- !Sep 8, 4:22 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $27.98 cash available; close=$1127.28.
- ?Sep 8, 1:24 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $27.98 cash available; close=$1127.28.
- !Sep 8, 1:24 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $5.80 cash available; close=$1123.32.
- ?Sep 8, 11:25 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $5.80 cash available; close=$1123.32.
- !Sep 8, 11:25 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $67.76 cash available; close=$1148.53.
- ?Sep 4, 7:23 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip_no_cash
Wanted to buy but only $10524.93 cash available; close=$1149.36.
- !Sep 4, 7:23 PMsignal
Agent 4 — Dip Buyer (Frozen) — insufficient_capital
LLY is down 11.1% from its 30-day high, but there is no evidence of genuine fundamental deterioration — no guidance cuts, no accounting issues, and no sector collapse. In fact, Lilly is actively deploying capital via a $2.88B autoimmune acquisition, signaling strategic expansion beyond its obesity franchise. The post-earnings drift of -2.7% is modest and consistent with normal mean-reversion pressure, and the macro backdrop (5Y5Y inflation forward at 2.33%, modestly elevated but not alarming) does not represent a systemic headwind for large-cap pharma specifically.
- ?Sep 4, 4:24 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $67.76 cash available; close=$1148.53.
- !Sep 4, 4:24 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $48.94 cash available; close=$1140.42.
- ?Sep 4, 2:25 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $48.94 cash available; close=$1140.42.
- !Sep 4, 2:25 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $43.21 cash available; close=$1144.21.
- ?Sep 4, 1:25 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $43.21 cash available; close=$1144.21.
- !Sep 4, 1:25 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $18.86 cash available; close=$1146.76.
- ?Sep 4, 12:24 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $18.86 cash available; close=$1146.76.
- !Sep 4, 12:24 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $48.83 cash available; close=$1159.54.
- ?Sep 3, 4:22 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $48.83 cash available; close=$1159.54.
- !Sep 3, 4:22 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $106.12 cash available; close=$1157.91.
- ?Sep 3, 3:23 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $106.12 cash available; close=$1157.91.
- !Sep 3, 3:23 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $41.52 cash available; close=$1160.81.
- ?Sep 3, 1:23 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $41.52 cash available; close=$1160.81.
- !Sep 3, 1:23 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $23.32 cash available; close=$1152.56.
- ?Sep 3, 11:26 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $23.32 cash available; close=$1152.56.
- !Sep 3, 11:26 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $26.70 cash available; close=$1159.72.
- ?Sep 2, 4:23 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $26.70 cash available; close=$1159.72.
- !Sep 2, 4:23 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
LLY is a fundamentally dominant GLP-1 franchise with no hard veto conditions — no guidance cuts, no going-concern language, and earnings are 57 days away (no imminent binary event). The health care sector is outperforming (rank 2 of 11, +5.32pts 30d vs SPY), today's sector flow proxy is strongly positive (+$8.8M), and recent headlines are mildly constructive (record stock price coverage, M&A diversification via Merida deal). The 10.3% pullback from the 30-day high appears macro/rate-driven rather than fundamental, consistent with mean-reversion potential. Anchoring to the ~55-60% base rate for S&P 500 large-caps with intact fundamentals, the clean earnings runway and positive sector tone nudge the probability modestly upward.
- ✓Sep 2, 10:31 AMdecisionacted
Agent 7 — Day Trader — decide: buy
LLY is up 1.53% intraday, a moderate move below the 2-5% threshold that would signal high-conviction institutional flow. The most recent headline (Zepbound study positive for investors) provides a mild fundamental catalyst supporting the upside direction. With 315 minutes remaining (full session essentially), there is ample time for continuation. However, the macro backdrop is a mild headwind: 5-year forward inflation expectations are running 1.7 sigma above trend, which pressures rate-sensitive and growth/premium-multiple names like LLY. The move magnitude is meaningful but not dramatic, suggesting no extreme euphoria or short-squeeze dynamic at play. No reversal signals are evident. Net assessment: modest continuation bias — the news catalyst is real, time is ample, but the elevated inflation expectations environment slightly tempers enthusiasm for a high-multiple biotech/pharma name. Probability sits in the ordinary momentum range.
- ▢Sep 1, 8:00 PMjournal
Agent 7 — Day Trader opened long 2 @ $1,177.77
- ▣Sep 1, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 2 @ $1,158.66 (-$38.22)
Long stop: close $1158.66 ≤ stop $1160.10
- ?Sep 1, 4:22 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $9.09 cash available; close=$1160.00.
- !Sep 1, 4:22 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $14.99 cash available; close=$1158.20.
- ?Sep 1, 3:26 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $14.99 cash available; close=$1158.20.
- !Sep 1, 3:26 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $3.57 cash available; close=$1158.59.
- ?Aug 31, 4:22 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.57 cash available; close=$1158.59.
- !Aug 31, 4:22 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.24 cash available; close=$1159.53.
- ?Aug 31, 3:24 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.24 cash available; close=$1159.53.
- !Aug 31, 3:24 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $8.87 cash available; close=$1155.29.
- ?Aug 31, 2:25 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.87 cash available; close=$1155.29.
- !Aug 31, 2:25 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Step 1 — No hard vetoes triggered: the drop is 10.6% (well below the 35% threshold), earnings are 59 days away (outside the ≤14-day imminent window), and neither the 10-Q nor 8-K filings contain any disclosed metrics suggesting guidance cuts, covenant breaches, or going-concern language. Step 2 — Signal scoring: Health Care (XLV) is ranked 2 of 11 by 30-day relative strength and shows +2.75pts vs SPY over 30 days, meaning this is a single-stock dip against an outperforming sector (-1 idiosyncratic signal); no cluster insider buying (only one small director award, not a purchase, 0); no options flow data (neutral, 0); no news headlines (absence of bad news is neutral, 0); earnings 59 days away (+1 clean runway); macro is benign with VIX at 14.43 (2nd percentile, low fear, +1); 2Y yield at 4.20% is below the 4.5% structural headwind threshold for a growth/duration-sensitive name like LLY (neutral, 0). Net signal score: +2 - 1 = +1. Step 3 — Marginal positive case with no fundamental impairment and no idiosyncratic red flags beyond the sector-relative underperformance. LLY is a fundamentally strong mega-cap pharma with a dominant GLP-1 franchise. A +1 net score with no impairment supports a probability consistent with the base rate, slightly adjusted downward for the idiosyncratic nature of the drop relative to the outperforming sector.
- ✓Aug 31, 2:24 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
LLY is a fundamentally strong mega-cap pharma (GLP-1 franchise, robust pipeline) and the 10.6% drop from the 30-day high is moderate and not explained by any confirmed negative catalyst — no adverse headlines, no warning in the 10-Q metrics, no insider sales. The Health Care sector ranks 2nd of 11 by 30-day relative strength with positive 30-day outperformance vs. SPY, suggesting this dip is at least partly idiosyncratic or a short-term pullback within a strong sector. Earnings are 59 days away, removing near-term binary risk. The single small insider award is informational but not a cluster buy signal. VIX at the 2nd percentile indicates a very calm macro backdrop, which is modestly supportive of risk assets.
- ?Aug 31, 11:26 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LLY is down 1.55% intraday, which is a moderate but not outsized move for this high-priced name. There are no recent headlines to explain the move, suggesting either broad market pressure or quiet institutional selling rather than a catalyst-driven flush. The macro context (elevated mortgage rates) is not directly relevant to LLY as a pharmaceutical/GLP-1 name, so no meaningful sector tailwind or headwind is introduced. With 260 minutes remaining (over 4 hours), there is ample time for continuation, which is a mild positive for the down thesis. However, the move magnitude at 1.55% is below the 2-5% threshold that would constitute strong directional conviction evidence on its own. Without supporting news, a sector catalyst, or a clearly identifiable momentum pattern, this reads as an ordinary drift lower. No reversal signals are evident, but no strong continuation pressure either. Assigning baseline continuation probability of 0.50 — the move is real but lacks the conviction markers to push higher confidence.
- !Aug 31, 11:26 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
LLY is down 1.55% intraday, which is a moderate but not outsized move for this high-priced name. There are no recent headlines to explain the move, suggesting either broad market pressure or quiet institutional selling rather than a catalyst-driven flush. The macro context (elevated mortgage rates) is not directly relevant to LLY as a pharmaceutical/GLP-1 name, so no meaningful sector tailwind or headwind is introduced. With 260 minutes remaining (over 4 hours), there is ample time for continuation, which is a mild positive for the down thesis. However, the move magnitude at 1.55% is below the 2-5% threshold that would constitute strong directional conviction evidence on its own. Without supporting news, a sector catalyst, or a clearly identifiable momentum pattern, this reads as an ordinary drift lower. No reversal signals are evident, but no strong continuation pressure either. Assigning baseline continuation probability of 0.50 — the move is real but lacks the conviction markers to push higher confidence.
- ?Aug 31, 9:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LLY is down 2.16% intraday with 355 minutes remaining — well into the session but still substantial time for continuation. No headline catalyst is present, but as noted in guidance, absence of news does not disqualify momentum; someone with size is selling. LLY is a large-cap pharma with idiosyncratic flow dynamics often driven by institutional repositioning, pipeline sentiment, or sector rotation. The macro context (elevated mortgage rates) is not directly relevant to LLY, neither supporting nor fading this move. With no reversal signal evident and meaningful time left in the session, the base case is mild continuation of the downward pressure. However, a -2.16% move in a stock of this magnitude may also attract dip buyers in the afternoon, and without volume data or a clear catalyst to sustain selling, conviction is limited. Probability is set modestly above 0.5 — enough to trigger a short position given bounded downside risk — but not elevated to the 0.65+ range that would require clearer continuation signals such as confirmed volume or sector headwinds.
- !Aug 31, 9:50 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
LLY is down 2.16% intraday with 355 minutes remaining — well into the session but still substantial time for continuation. No headline catalyst is present, but as noted in guidance, absence of news does not disqualify momentum; someone with size is selling. LLY is a large-cap pharma with idiosyncratic flow dynamics often driven by institutional repositioning, pipeline sentiment, or sector rotation. The macro context (elevated mortgage rates) is not directly relevant to LLY, neither supporting nor fading this move. With no reversal signal evident and meaningful time left in the session, the base case is mild continuation of the downward pressure. However, a -2.16% move in a stock of this magnitude may also attract dip buyers in the afternoon, and without volume data or a clear catalyst to sustain selling, conviction is limited. Probability is set modestly above 0.5 — enough to trigger a short position given bounded downside risk — but not elevated to the 0.65+ range that would require clearer continuation signals such as confirmed volume or sector headwinds.
- ?Aug 26, 2:50 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LLY is down 3.24% intraday, a meaningful move representing real institutional flow. No headlines are available to explain the catalyst, but the magnitude itself signals conviction selling. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a mild headwind for high-multiple growth/healthcare names like LLY (elevated rates compress valuations). However, with only 55 minutes remaining until the forced close, the window for further meaningful downside is limited. At this stage of the session, large moves often stabilize or see some mean reversion as sellers who drove the move earlier have largely executed. The absence of a news catalyst also slightly increases the chance this was a technical or derivative-driven flush that may not have fresh sellers behind it. Balancing the momentum signal (favoring continuation) against the limited time and late-session stabilization tendency, this is a marginal continuation setup. Probability sits just above the 0.5 threshold — there is no strong reason to expect a reversal, but no clear evidence of sustained selling pressure into the close either.
- !Aug 26, 2:50 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
LLY is down 3.24% intraday, a meaningful move representing real institutional flow. No headlines are available to explain the catalyst, but the magnitude itself signals conviction selling. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a mild headwind for high-multiple growth/healthcare names like LLY (elevated rates compress valuations). However, with only 55 minutes remaining until the forced close, the window for further meaningful downside is limited. At this stage of the session, large moves often stabilize or see some mean reversion as sellers who drove the move earlier have largely executed. The absence of a news catalyst also slightly increases the chance this was a technical or derivative-driven flush that may not have fresh sellers behind it. Balancing the momentum signal (favoring continuation) against the limited time and late-session stabilization tendency, this is a marginal continuation setup. Probability sits just above the 0.5 threshold — there is no strong reason to expect a reversal, but no clear evidence of sustained selling pressure into the close either.
- ?Aug 26, 1:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LLY is down 2.88% intraday — a meaningful move that represents real institutional flow. With 135 minutes remaining, there is enough time for continuation into the close. However, there are no catalysts (no headlines) to drive a narrative-based continuation, which limits conviction. The macro context shows elevated 5-year forward inflation expectations (T5YIFR 1.6σ above trend), which is broadly rate-sensitive but LLY as a large-cap pharma/biotech is not directly rate-sensitive in the way that REITs or utilities would be — this macro factor is essentially neutral for the ticker. The absence of a news catalyst means this could be a technical breakdown or quiet distribution day rather than a news-driven flush that tends to overshoot. With no reversal signal evident and the move already at the lower end of the 2-5% meaningful range, modest momentum continuation is slightly favored but not with high conviction. Probability set just above threshold reflecting ordinary momentum with no strong reason to expect an intraday reversal, but also no strong reason to expect aggressive continuation.
- !Aug 26, 1:30 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
LLY is down 2.88% intraday — a meaningful move that represents real institutional flow. With 135 minutes remaining, there is enough time for continuation into the close. However, there are no catalysts (no headlines) to drive a narrative-based continuation, which limits conviction. The macro context shows elevated 5-year forward inflation expectations (T5YIFR 1.6σ above trend), which is broadly rate-sensitive but LLY as a large-cap pharma/biotech is not directly rate-sensitive in the way that REITs or utilities would be — this macro factor is essentially neutral for the ticker. The absence of a news catalyst means this could be a technical breakdown or quiet distribution day rather than a news-driven flush that tends to overshoot. With no reversal signal evident and the move already at the lower end of the 2-5% meaningful range, modest momentum continuation is slightly favored but not with high conviction. Probability set just above threshold reflecting ordinary momentum with no strong reason to expect an intraday reversal, but also no strong reason to expect aggressive continuation.
- ?Aug 26, 12:05 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
LLY is down 3.47% intraday, a meaningful move reflecting real institutional selling pressure. No headlines are available to attribute the move, but absence of news does not negate the momentum signal — large-cap pharma moves of this magnitude typically reflect portfolio rebalancing, sector rotation, or derivative-driven flows. The macro context shows the 5-year forward inflation rate (T5YIFR) running 1.6σ above trend, which is a mild headwind for long-duration growth/biotech-adjacent names like LLY as rate-sensitive sectors reprice. With 220 minutes remaining until forced close, there is ample time for continuation — the position would not be time-constrained. However, a 3.47% move in a $1200+ stock is already substantial, and without a clear catalyst or news driver, mean-reversion risk is non-trivial as value buyers may step in at these levels. Balancing: meaningful momentum (favors continuation), elevated inflation expectations (mild headwind for LLY's valuation), no reversal pattern evident, and sufficient time remaining — this resolves to a modest continuation lean. Probability set at 0.54, above threshold but not a high-conviction setup.
- !Aug 26, 12:05 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
LLY is down 3.47% intraday, a meaningful move reflecting real institutional selling pressure. No headlines are available to attribute the move, but absence of news does not negate the momentum signal — large-cap pharma moves of this magnitude typically reflect portfolio rebalancing, sector rotation, or derivative-driven flows. The macro context shows the 5-year forward inflation rate (T5YIFR) running 1.6σ above trend, which is a mild headwind for long-duration growth/biotech-adjacent names like LLY as rate-sensitive sectors reprice. With 220 minutes remaining until forced close, there is ample time for continuation — the position would not be time-constrained. However, a 3.47% move in a $1200+ stock is already substantial, and without a clear catalyst or news driver, mean-reversion risk is non-trivial as value buyers may step in at these levels. Balancing: meaningful momentum (favors continuation), elevated inflation expectations (mild headwind for LLY's valuation), no reversal pattern evident, and sufficient time remaining — this resolves to a modest continuation lean. Probability set at 0.54, above threshold but not a high-conviction setup.
- ?Aug 5, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-07-30 through 2026-08-04, LLY carved out a tight low-price cluster: five consecutive DOWN days compressed the close from $1,210.02 down to $1,115.68, with volume running in a narrow 2.9M–3.1M band — elevated but not extreme, consistent with orderly selling exhaustion rather than panic distribution. Today, 2026-08-05, the stock broke decisively above that entire five-session cluster, closing at $1,168.78 (+4.76%) on 5.5M shares — a volume z-score of +6.68 against the trailing 20-day ADV of 2.4M, more than 2× the cluster-period volume and the highest volume in the entire 20-day path. In SIR's 2-D scatter, the path shifted sharply up-and-right in a single session, the hallmark "cluster_break_up" signature: fresh, large-lot demand absorbed the float that had been distributed through the prior down-leg, and price responded with conviction. Risks: A single-bar event is inherently fragile under the SIR methodology — if the next 1–2 sessions fail to hold above the cluster ceiling (~$1,148–$1,155) on declining or average volume, the break could be a one-day reversal/oversold bounce rather than genuine accumulation, invalidating the bullish read. Additionally, the macro context flags a 5-year inflation breakeven (T5YIE) at 1.9σ below trend, which could signal deflationary growth fears that weigh disproportionately on high-multiple Health Care names like LLY if the risk-off tone reasserts.
- ✓Aug 5, 11:10 AMdecisionacted
Agent 7 — Day Trader — decide: buy
LLY is up 2.45% on strong fundamental catalysts: revenue beat, raised outlook, Mounjaro sales doubling, and CEO commentary reinforcing a bullish growth narrative around retatrutide as the next weight-loss driver. The headlines are clustered around earnings/guidance beats — this is the kind of high-conviction institutional flow that tends to persist into the close as analysts update models, funds add exposure, and momentum players pile in. With 275 minutes remaining there is ample time for continuation. The macro backdrop is mildly supportive (low 5Y breakeven inflation = lower discount rate pressure on growth stocks like LLY). Novo Nordisk pipeline concerns in the same headline cycle could further shift GLP-1 market share sentiment toward LLY. No reversal pattern is evident — the move appears to be a clean breakout on volume rather than a fade off morning highs. The only modest dampener is that much of the initial gap-up reaction may already be priced in from the pre-market/open surge, but the raised guidance and CEO confidence in next-gen pipeline typically sustains buying pressure throughout the session. Overall, this is a clear earnings-driven momentum setup with time, news, and sector tailwinds all aligned.
- ✓Aug 5, 10:05 AMdecisionacted
Agent 7 — Day Trader — decide: buy
LLY is up 6.46% intraday, a move of significant magnitude that represents real institutional conviction and substantial flow. With 340 minutes remaining (well over 5 hours of trading), there is ample time for continuation. The absence of headlines is not disqualifying — large pharma moves of this size frequently occur on clinical data, FDA decisions, or earnings catalysts that may not yet be fully reflected in aggregated feeds. The macro context (5Y breakeven inflation 1.9σ below trend) is mildly risk-on supportive in that lower inflation expectations reduce discount rate pressure on growth/large-cap names like LLY, though LLY's move is almost certainly idiosyncratic rather than macro-driven. No reversal pattern is evident from available data — the move is described as a clean directional thrust without indication of fading off highs. Counterweights: the 6.46% magnitude is large enough that some profit-taking into the close is plausible, and without confirmed news context there is uncertainty about whether the catalyst is fully priced. On balance, momentum of this size with this much time remaining favors continuation at a modest probability above the action threshold.
- ?Aug 5, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LLY is a fundamentally strong company (GLP-1/obesity franchise, robust pipeline), but the setup is dominated by imminent earnings risk — the company reports tomorrow (2026-08-05), making this a pure binary event. The 10.3% dip from the 30-day high may itself be pre-earnings repositioning rather than a fundamental impairment, but with no news, filings, insider activity, or options flow to confirm an overreaction thesis, there is no edge. Additionally, the Healthcare sector is underperforming SPY today (flow proxy sharply negative at -3.4M), suggesting sector-wide pressure rather than an idiosyncratic overreaction with a clear recovery catalyst. High 10Y yield (4.75%) is a mild headwind for high-multiple names like LLY.
- !Aug 5, 7:03 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
LLY is a fundamentally strong company (GLP-1/obesity franchise, robust pipeline), but the setup is dominated by imminent earnings risk — the company reports tomorrow (2026-08-05), making this a pure binary event. The 10.3% dip from the 30-day high may itself be pre-earnings repositioning rather than a fundamental impairment, but with no news, filings, insider activity, or options flow to confirm an overreaction thesis, there is no edge. Additionally, the Healthcare sector is underperforming SPY today (flow proxy sharply negative at -3.4M), suggesting sector-wide pressure rather than an idiosyncratic overreaction with a clear recovery catalyst. High 10Y yield (4.75%) is a mild headwind for high-multiple names like LLY.
- ?Aug 5, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
STEP 1 HARD VETO TRIGGERED: Earnings are imminent in 2 days (2026-08-05), which is a binary single-print event capable of swinging the stock ±10% or more. The override condition requires all three of: cluster insider buys, unusual call flow, AND clearly strong fundamentals — none of these are confirmed (no Form 4 activity, no options flow data, no recent filings available). Net signal score is effectively 0 or negative: no positive signals fire (no cluster buy, no unusual calls, drop is only 10.3% which does not reach the +1 mean-reversion threshold of ≥15%, earnings are imminent which would be -1 if not already vetoed, sector flow proxy is negative). The veto stands and the trade is blocked.
- !Aug 5, 7:03 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
STEP 1 HARD VETO TRIGGERED: Earnings are imminent in 2 days (2026-08-05), which is a binary single-print event capable of swinging the stock ±10% or more. The override condition requires all three of: cluster insider buys, unusual call flow, AND clearly strong fundamentals — none of these are confirmed (no Form 4 activity, no options flow data, no recent filings available). Net signal score is effectively 0 or negative: no positive signals fire (no cluster buy, no unusual calls, drop is only 10.3% which does not reach the +1 mean-reversion threshold of ≥15%, earnings are imminent which would be -1 if not already vetoed, sector flow proxy is negative). The veto stands and the trade is blocked.
- ▢Aug 4, 8:00 PMjournal
Agent 7 — Day Trader opened long 2 @ $1,142.97
- ▣Aug 4, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 2 @ $1,166.79 (+$47.64)
EOD forced close — day trader never carries overnight
- ▢Aug 4, 8:00 PMjournal
Agent 7 — Day Trader opened long 2 @ $1,187.75
- ▣Aug 4, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 2 @ $1,167.02 (-$41.46)
Long stop: close $1167.02 ≤ stop $1169.93
- ?Aug 4, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
STEP 1 HARD VETO TRIGGERED: Earnings are imminent in 2 days (2026-08-05), which is a binary single-print event capable of swinging the stock ±10% or more. The override condition requires all three of: cluster insider buys, unusual call flow, AND clearly strong fundamentals — none of these are confirmed (no Form 4 activity, no options flow data, no recent filings available). Net signal score is effectively 0 or negative: no positive signals fire (no cluster buy, no unusual calls, drop is only 10.3% which does not reach the +1 mean-reversion threshold of ≥15%, earnings are imminent which would be -1 if not already vetoed, sector flow proxy is negative). The veto stands and the trade is blocked.
- !Aug 4, 6:05 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
STEP 1 HARD VETO TRIGGERED: Earnings are imminent in 2 days (2026-08-05), which is a binary single-print event capable of swinging the stock ±10% or more. The override condition requires all three of: cluster insider buys, unusual call flow, AND clearly strong fundamentals — none of these are confirmed (no Form 4 activity, no options flow data, no recent filings available). Net signal score is effectively 0 or negative: no positive signals fire (no cluster buy, no unusual calls, drop is only 10.3% which does not reach the +1 mean-reversion threshold of ≥15%, earnings are imminent which would be -1 if not already vetoed, sector flow proxy is negative). The veto stands and the trade is blocked.
- ?Aug 4, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip_no_cash
Wanted to buy but only $1071.54 cash available; close=$1116.24.
- ?Aug 4, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LLY is a fundamentally strong company (GLP-1/obesity franchise, robust pipeline), but the setup is dominated by imminent earnings risk — the company reports tomorrow (2026-08-05), making this a pure binary event. The 10.3% dip from the 30-day high may itself be pre-earnings repositioning rather than a fundamental impairment, but with no news, filings, insider activity, or options flow to confirm an overreaction thesis, there is no edge. Additionally, the Healthcare sector is underperforming SPY today (flow proxy sharply negative at -3.4M), suggesting sector-wide pressure rather than an idiosyncratic overreaction with a clear recovery catalyst. High 10Y yield (4.75%) is a mild headwind for high-multiple names like LLY.
- ?Aug 4, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
LLY is a fundamentally strong company (GLP-1/obesity franchise, robust pipeline), but the setup is dominated by imminent earnings risk — the company reports tomorrow (2026-08-05), making this a pure binary event. The 10.3% dip from the 30-day high may itself be pre-earnings repositioning rather than a fundamental impairment, but with no news, filings, insider activity, or options flow to confirm an overreaction thesis, there is no edge. Additionally, the Healthcare sector is underperforming SPY today (flow proxy sharply negative at -3.4M), suggesting sector-wide pressure rather than an idiosyncratic overreaction with a clear recovery catalyst. High 10Y yield (4.75%) is a mild headwind for high-multiple names like LLY.
- ?Aug 4, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
STEP 1 HARD VETO TRIGGERED: Earnings are imminent in 2 days (2026-08-05), which is a binary single-print event capable of swinging the stock ±10% or more. The override condition requires all three of: cluster insider buys, unusual call flow, AND clearly strong fundamentals — none of these are confirmed (no Form 4 activity, no options flow data, no recent filings available). Net signal score is effectively 0 or negative: no positive signals fire (no cluster buy, no unusual calls, drop is only 10.3% which does not reach the +1 mean-reversion threshold of ≥15%, earnings are imminent which would be -1 if not already vetoed, sector flow proxy is negative). The veto stands and the trade is blocked.
- ▢Jun 3, 8:00 PMjournal
Agent 7 — Day Trader opened long 1 @ $1,133.82
- ▣Jun 3, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 1 @ $1,123.61 (-$10.21)
EOD forced close — day trader never carries overnight
- ▢May 28, 8:00 PMjournal
Agent 7 — Day Trader opened long 1 @ $1,126.80
- ▣May 28, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 1 @ $1,108.10 (-$18.71)
Long stop: close $1108.10 ≤ stop $1109.90
- ▢May 27, 8:00 PMjournal
Agent 7 — Day Trader opened long 1 @ $1,111.71
- ▣May 27, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 1 @ $1,145.22 (+$33.51)
Long target: close $1145.22 ≥ target $1145.06
- ▢May 11, 8:00 PMjournal
Agent 7 — Day Trader opened long 2 @ $986.89
- ▣May 11, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 2 @ $967.06 (-$39.65)
Long stop: close $967.06 ≤ stop $972.08